Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: 10.1038/leu.2017.253
- Event
-
Veröffentlichung
- (where)
-
Aachen
- (who)
-
Universitätsbibliothek der RWTH Aachen
- (when)
-
2017
- DOI
-
10.18154/RWTH-CONV-220244
- URN
-
urn:nbn:de:101:1-2018101807093127579814
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:55 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Universitätsbibliothek der RWTH Aachen
Time of origin
- 2017
Other Objects (12)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
STAT3-mediated therapy resistance of malignant stem cells in chronic myeloid leukemia (CML)
Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
CML
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
KU-CHEN # CML
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
STAT3-mediated therapy resistance of malignant stem cells in chronic myeloid leukemia (CML)
Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
CML
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
KU-CHEN # CML
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
STAT3-mediated therapy resistance of malignant stem cells in chronic myeloid leukemia (CML)
Initial decline of BCR-ABL transcript levels as early prognostic marker for patients with chronic myeloid leukemia (CML) treated with imatinib
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
CML
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV